Richard W. Allen
Trade Performance Intelligence
Score: 6/10Performance calculated from trade date to most recent market close. Real-time stock data from Financial Modeling Prep. This is not financial advice.
Stock Price at Trade vs. Today
Real market data showing how each stock moved since the congress member traded it.
Suspicious Timing Detected
1 flagThese flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
Connected Legislative Activity
7 signalsThese bills and contracts share tickers or sectors with this filing's trades.
RESULTS Act
The RESULTS Act (HR5269) aims to stabilize Medicare reimbursement rates for clinical diagnostic laboratory tests, preventing future payment reductions. This bill is in the early stages of the legislative process, having been introduced and referred to two House committees. Its current impact on market prices for diagnostic testing companies is not yet significant due to its early legislative stage.
DeOndra Dixon INCLUDE Project Act of 2025
The DeOndra Dixon INCLUDE Project Act of 2025 (HR3491) has been introduced in the House and referred to the Committee on Energy and Commerce. This bill authorizes the NIH to establish a dedicated program for Down syndrome research, which could increase demand for genetic sequencing, diagnostic services, and pharmaceutical development. While the bill does not appropriate funds, it sets the framework for future funding opportunities.
Lowering Broadband Costs for Consumers Act of 2025
The 'Lowering Broadband Costs for Consumers Act of 2025' (HR4032) mandates increased Universal Service Fund contributions from broadband and 'edge providers,' directly raising operating costs for major internet service providers and large technology companies. This will reduce profit margins for affected companies. The bill is in the early stages, having been referred to committee, but has a companion bill (S1651) and 23 cosponsors, indicating moderate legislative momentum.
Ellie’s Law
Ellie's Law directs federal funding to the National Institute of Neurological Disorders and Stroke (NINDS) for unruptured intracranial aneurysm research, diagnostics, and treatment development. This creates new revenue opportunities for medical device companies, diagnostic firms, and life science research tool providers. The bill establishes a clear funding mechanism for neurological innovation.
BRAIN Act
The BRAIN Act (HR2767) was introduced in the House and referred to committee, aiming to increase research and awareness for brain tumor treatment. This legislation, if passed, would create new grant opportunities and research networks, directly benefiting oncology and neuroscience-focused pharmaceutical, biotech, diagnostic, and life science tool companies. The bill is in an early stage but has a companion bill (S1330) in the Senate, indicating bipartisan and bicameral support.
Reducing Hereditary Cancer Act
The Reducing Hereditary Cancer Act (HR4752) mandates Medicare coverage for germline mutation testing and associated preventive surgeries, directly expanding the addressable market for genetic testing and cancer diagnostics. This bill, currently in the early stages of referral to two committees, creates a substantial new revenue stream for companies providing these services. Companies like Illumina ($ILMN) and Labcorp ($LH) have seen positive 7-day changes of +5.74% and +4.12% respectively, indicating market anticipation.
SEPSIS Act
The SEPSIS Act (S.1929) establishes new federal programs for sepsis research, diagnosis, and treatment, creating new revenue streams for medical diagnostics, device manufacturers, and clinical research companies. Senate Majority Leader Schumer's sponsorship and a House companion bill (HR7116) indicate strong legislative momentum for this early-stage bill. The bill does not specify a funding amount, but authorizes programs that would require future appropriations.
Live Charts
Other Filings by Richard W. Allen
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.